用多式人工智能解决痴呆症临床试验中的"金头发问题"
Andrew E Welchman1, Zoe Kourtzi2
1Prodromic Ltd, Milton Hall, Ely Road, Milton, Cambridge CB24 6WZ, UK.
The journal of prevention of Alzheimer's disease
|December 1, 2025
概括
人工智能 (AI) 可以通过识别正确的患者来改善阿尔茨海默病和相关痴呆症 (ADRD) 临床试验. 这种精确的方法提高了治疗的有效性,并加速了对痴呆症护理的新疗法的开发.
科学领域:
- 神经科学是一个神经科学.
- 医疗信息学 医疗信息学
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病和相关痴呆症 (ADRD) 治疗方法的开发面临着由于患者异质性和诊断局限性的挑战.
- 目前的临床试验设计难以选择将从新型治疗中受益的患者,这会影响成功率.
研究的目的:
- 探索人工智能 (AI),特别是多模式机器学习如何解决ADRD患者分层挑战.
- 展示AI在优化临床试验患者选择和在现实环境中实现精确治疗方面的潜力.
主要方法:
- 检查了识别痴呆症阶段和亚型的概念框架.
- 从阿尔茨海默病治疗临床试验中审查数据.
- 讨论了人工智能融入临床工作流程,模型解释性,概括性和伦理方面的问题.
主要成果:
- 人工智能引导的患者分层可以通过确保适当的患者纳入来显著改善临床试验结果.
- 人工智能可以降低试验成本,提高患者招募效率.
- 智能分析与科学和临床专业知识相结合,可以加速诊断和治疗发现.
结论:
- 人工智能在临床试验中为"金发问题"提供了强有力的解决方案,使得ADRD的精准医学成为可能.
- 将人工智能整合到医疗保健工作流程中对于改变痴呆症护理和改善全球患者结果至关重要.
- 解决算法偏差和确保模型通用性对于人工智能在痴呆症治疗中的道德和有效部署至关重要.
相关概念视频
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


